linjc16/ctgov huggingface dataset:
Diagnosis of Cardiac Amyloidosis With 99mTc-PYP; Comparison Between Planar Imaging, SPECT/CT and Cardiac-dedicated CZT Camera

Study Overview
=================
Brief Summary
-----------------
Patients will undergo clinical and laboratory assessment, as well as imaging tests, at the discretion of the attending cardiologist and will be referred at their discretion to perform cardiac mapping using 99mTc-PYP. On the day of the examination, the examiner will be admitted to the Office of Nuclear Medicine and will be admitted to administrative. Before conducting the test, the subject will undergo a brief interview by a physician, receive an explanation of the study and, if agreed, sign an agreement to perform a further examination on the CZT camera. The patient will, as is customary, be installed on Vanflon 22 G periphery, through which a 15 millikiric (mCi) of

Official Title
-----------------
Diagnosis of Cardiac Amyloidosis With 99mTc-PYP; Comparison Between Planar Imaging, SPECT/CT and Cardiac-dedicated CZT Camera

Conditions
-----------------
Cardiac Amyloidosis

Intervention / Treatment
-----------------
* Diagnostic Test: Spect scan with mTc99-PYP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A. Patients undergoing cardiac amyloidosis clinic at Tel Aviv Medical Center and there is a clinical suspicion of having cardiac amyloidosis. B. Patients who performed will be referred for mapping using 99mTc-PYP and sign a consent form to take another photograph, under the cardiac-dedicated CZT camera Exclusion Criteria: 1.None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cardiac amyloidosis patients<br> | Diagnostic Test: Spect scan with mTc99-PYP<br>* . About forty-five minutes after the injection mTc99-PYP , flanner and SPECT-CT mappings will be performed and then the patient will move to the CZT camera and undergo another photograph.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients who preformed mTc99-PYP for cardiac amyloidosis imaging. | Evaluation of cardiac amyloidosis imaging with mTc99-PYP cardiac-dedicated CZT camera | 1 year |
A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate the safety, tolerability and effectiveness of BTA798 on shortening the length and reducing the symptoms of human rhinovirus infection (also known as the common cold), controlling asthma symptoms, and lowering the risk of asthma symptoms worsening in subjects with asthma.

Detailed Description
-----------------
Subjects with a previous diagnosis of asthma will be pre screened within 90 days prior to enrolment. If a subject develops symptoms of human rhinovirus (HRV) infection they will visit the site for assessment. Symptomatic subjects meeting all eligibility criteria will be invited to enroll.

Official Title
-----------------
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

Conditions
-----------------
Rhinovirus

Intervention / Treatment
-----------------
* Drug: BTA798
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female subjects aged 18-70 years Diagnosis of asthma consistent with Global Initiative for Asthma (GINA) steps 1 to 3 Presumptive human rhinovirus infection Exclusion Criteria: Current severe asthma exacerbation Severe asthma, GINA steps 4 or higher Uncontrolled or clinically significant medical condition, disease or event which could impact subject safety and/or study evaluations and/or compliance to the protocol Current smoker, ex-smoker of <1 year, or history of smoking >/=10 pack years.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BTA798<br> | Drug: BTA798<br>* BTA798 twice daily<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Placebo twice daily<br>* Other names: Glucose;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire | Daily Change in WURSS-21 Severity Score Averaged over Days 2 to 4. The Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire is an evaluative illness-specific outcomes instrument designed to assess the severity of cold symptoms and the impact of the common cold (range 0-140), with higher scores indicating more symptoms and functional impairment. | Days 2-4 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Human rhinovirus, Aviragen Therapeutics, Inc., Aviragen Therapeutics, Aviragen
Polscope Sperm: A Non-invasive Method to Assess DNA Damage in Individual Sperm

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to find a non-invasive way to discover DNA (deoxyribonucleic acid, which is the genetic material inside your cells) alterations in the sperm's head, in the near future leading us to choose the good sperm in a simplified manner. This could then increase chances of a successful in-vitro fertilization (IVF) treatment when there are sperm abnormalities.

Detailed Description
-----------------
If you take part in this study, Your physician is asking you to provide a semen sample as you already would. The sample will be taken to the IVF lab which would occur if you were not involved in this research. The part that would be thrown away is then further analyzed under a polarized light microscope. The sample is exposed to ultraviolet (UV) light for a period of 20 minutes after which it is analyzed under the microscope again, looking for any changes when compared the sample that was not exposed to UV light. The sample is then discarded. Your name will be removed from the sample after the regular semen analysis is done; therefore there will be no way of associating the research results with you. No information will be needed from you and you will not be contacted in the future regarding this research.

Official Title
-----------------
A Non-invasive Method to Assess DNA Damage in Individual Sperm

Conditions
-----------------
DNA Damage, Other Complications Associated With Artificial Fertilization

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-60 years provide informed consent Already providing a semen sample as routine therapy in IVF Exclusion Criteria: -unable to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IVF
RAPID-RF: Remote Active Monitoring in Patients With Heart Failure

Study Overview
=================
Brief Summary
-----------------
The RAPID-RF Registry aims to characterize LATITUDE® Patient Management's alert feature: LATITUDE Active Monitoring™ by evaluating type and frequency of alert notifications and alert-related medical interventions. This registry will also assess clinical outcomes including quality of life and New York Heart Association Class changes over time, mortality, hospitalizations and heart failure-related event rates.

Official Title
-----------------
Remote Active Monitoring in Patients With Heart Failure

Conditions
-----------------
Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who meet current indications for a Guidant RF-enabled CRT-D device (e.g. CONTAK RENEWAL 3 RF family of CRT-D devices) which is compatible with the LATITUDE Communicator. Indications include: NYHA Class III, IV; EF of ≤ 35%; QRS duration of ≥ 120 ms; and optimized pharmacologic therapy Patients who have an analog telephone line compatible with the LATITUDE Communicator. The LATITUDE Communicator must be placed within 8 feet of where they sleep for successful remote interrogations to occur. Patients who receive the study components including the LATITUDE Communicator, weight scale, and blood pressure monitor Patients who are willing and capable of providing informed consent prior to implant and willing to participate in the RAPID-RF Registry Patients who remain in the clinical care of a RAPID-RF investigator at approved centers Exclusion Criteria: Patients who are expected to receive a heart transplant during the course of the study Patients who have received or who will receive a tricuspid valve prosthesis during the course of the study Patients who have previously received an implantable cardiac resynchronization device (e.g., biventricular pacemaker or biventricular ICD) Patients whose life expectancy is less than 12 months Patients who are currently enrolled in another observational registry or investigational study that could directly impact the treatment or outcome of the RAPID-RF Registry. Contact Guidant's Clinical Application Research Study (CARS) department to determine eligibility. Patients who are younger than 18 years of age Patients who are pregnant or plan to become pregnant during the study Patients who are unable or refuse to comply with the protocol requirements

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart Failure, Remote Monitoring, Implantable Device
Complications After Endosonography and Guided Bronchoscopy

Study Overview
=================
Brief Summary
-----------------
The present study aims to investigate prospectively and systematically the direct and indirect complications occurring within 30 days after guided-bronchoscopy and/or endosonography. The results of the study should reliably help clarify further incidence, pattern, risk factors, and outcomes for both immediate and late complications associated with these key diagnostic procedures.

Official Title
-----------------
30-DAY MORBIDITY, MORTALITY AND UNPLANNED HOSPITAL ADMISSIONS AFTER GUIDED-BRONCHOSCOPY AND ENDOSONOGRAPHY

Conditions
-----------------
Complication of Bronchoscopy

Intervention / Treatment
-----------------
* Diagnostic Test: Guided bronchoscopy and/or endosonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18 years, Indication to undergo bronchoscopy, endosonography, or both. Signed informed consent Exclusion Criteria: Absolute contraindications to the bronchoscopic examination based on international guidelines [31]. Platelet count <50000

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Guided bronchoscopy and/or endosonography|Endoscopic procedures aimed at sampling of intrathoracic lymph nodes or pulmonary lesions|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of severe complications |  | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall incidence of complications |  | 30 days | 
| Risk factors associated with severe complications |  | 30 days | 
| Rate of unplanned hospital admissions |  | 30 days | 
| Mortality |  | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endosonography, Guided bronchoscopy, Complications, Hospital admission, Lung cancer
The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23

Study Overview
=================
Brief Summary
-----------------
To compare the effect of lanthanum carbonate with calcium carbonate on serum FGF23 levels in hemodialysis patients.

Detailed Description
-----------------
The investigators enrolled patients on maintenance hemodialysis and randomized them to two groups. One group will receive lanthanum carbonate and another group will receive calcium carbonate. The investigators will compare serum FGF23 levels between two groups after they receive above medication for 6 months.

Official Title
-----------------
Compared the Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 With Calcium Carbonate in Hemodialysis Patients

Conditions
-----------------
Other Nonspecific Abnormal Serum Enzyme Levels

Intervention / Treatment
-----------------
* Drug: Lanthanum carbonate
* Drug: Calcium Carbonate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years old Chronic renal failure on maintenance hemodialysis 3 times a week for at least 3 months Serum calcium:8-10.5 mg/dL Serum phosphate:3.5-6 mg/dL(before washout period) Serum phosphate ≧6 mg/dL after washout period Serum i-PTH: 150-600 pg/mL Exclusion Criteria: Diabetes mellitus Post parathyroidectomy Life expectancy< 6 months Liver disease(hepatitis B,C or liver dysfunction) Severe gastrointestinal disorders or other severe comorbidity Poor compliance Intolerance to lanthanum or calcium carbonate Active infection Malnutrition(serum albumin<3 g/dL or clinical assessment) Kt/V< 1.2 (inadequate dialysis) Serum phosphate>7.5 mg/dL after washout period

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Lanthanum carbonate<br>Lanthanum carbonate 375mg 750 mg tid for 6 months | Drug: Lanthanum carbonate<br>* the effect on serum FGF23<br>* Other names: Fosrenol;|
| Active Comparator: Calcium carbonate<br>Calcium carbonate 500mg 1000 mg tid for 6 months | Drug: Calcium Carbonate<br>* Calcium carbonate 500mg 1000 mg tid for 6 months<br>* Other names: TOP-CAL(CaCO3);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum level of fibroblast growth factor |  | 6 months |
Bone Changes Assessment in Screw-Retained Maxillary Complete Denture With Electric Welded Framework Versus Cast One

Study Overview
=================
Brief Summary
-----------------
comparing bony changes around implants that will be joined by ametal framework either with electric weiling or with the conventional casting metal

Detailed Description
-----------------
joining multiple implants together in the edentulous arches is considered agood solution, using the conventional casting technique has many disadvantages due to lab errors and time and cost consuming on ,the other hand the study aims to owercome these disadvantages using electric welding metal framework.

Official Title
-----------------
Bone Changes Assessment in Screw-Retained Maxillary Implant Supported Complete Denture With Electric Welded Metal Framework Versus Cast One (Randomized Control,Split Mouth Trial)

Conditions
-----------------
Bone Resorption

Intervention / Treatment
-----------------
* Device: electric intraoral weilding
* Device: casting


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age range from 30 to 65 years old. Absence of any medical disorder that could complicate the Surgical phase or affect osseointegration. The patients must be completely edentulous. The patient must have enough bone height for implants minimum length of 10mm and a minimum diameter of 5 mm. Patients with good oral hygiene. Complete denture wearer. Adequate inter arch space for screw retained prosthesis. Absence of any intra-oral pathological condition. Exclusion Criteria: Patients with recent extraction(less than three months). Patients with inflamed ridge or candida infection. Patients with flappyridge. Parafunctional habits.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: electric welded metal framework<br>using electric welding device to intraorally join metal framework where the study aim to save time and cost and eliminate lab errors | Device: electric intraoral weilding<br>* weilding metal framework to the implants in completely edentulous maxilla using electric weilding device intraorally<br>|
| Experimental: conventional cast metal technique<br>using the conventional casting technique to join metal framework and compare it with the electric welding technique | Device: casting<br>* casting metal framework<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bony changes assessment | assessment of bone height changes around implants using digital periapical paralling imaging technique and the unit will be meagured in mm. | 12 months |
Functional Capacity and Quality of Life Following Septal Myectomy in Patients With HCM

Study Overview
=================
Brief Summary
-----------------
Investigators aim to assess changes in exercise capacity and quality of life after septal myectomy in patient with hypertrophic cardiomyopathy.

Detailed Description
-----------------
The objective of this study is to examine change in quality of life and functional capacity as respectively measured by, Quality of Life Questionnaires and six-minute walk test distance, following septal myectomy in patients with obstructive hypertrophic cardiomyopathy, as compared to prior to surgery.

Official Title
-----------------
Functional Capacity and Quality of Life Following SePtal Myectomy in patIents With Obstructive hypeRtrophIc cardiomyopaThy

Conditions
-----------------
Hypertrophic Cardiomyopathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Scheduled to undergo septal myectomy. Established diagnosis of obstructive HCM defined as: LVH Thickness ≥15mm left ventricular outflow tract gradient ≥50mmHg Exclusion Criteria: Prior septal myectomy or alcohol septal ablation Prior myocardial infarction Uncontrolled arrhythmias including ventricular tachycardia and atrial fibrillation Uncontrolled hypertension Angiographically documented coronary stenosis >50%, if available at time of screening Inability to provide informed consent Inability to walk without assistive devices Peripheral artery disease with claudication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No functional capacity testing<br>6 minute walk Quality of life Questionaire | |
| Functional Capacity Testing<br>6 minute walk Quality of Life Questionnaire Metabolic stress test | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Quality of Life Change in Summary Score | Mild improvement in Quality of Life summary score (increase in 5 points) as measured by Kansas City Cardiomyopathy Questionnaire -KCCQ | 1 year post myectomy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Quality of Life Change in Patient Reported Outcomes | Quality of Life as measured by The Patient-Reported Outcomes Measurement Information System (PROMIS) Questionnaire | 1 year post myectomy | 
| Change in Quality of Life Change in Duke's Activity Status Index (DASI) | Quality of Life as measured by the Duke's Activity Status Index (DASI) Questionnaire | 1 year post myectomy | 
| Change in functional capacity post myectomy | Functional capacity will be measured by 6 minute walk | 1 year post myectomy |